Amines or amino alcohols as glyt1 inhibitors

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I

• wherein
• R1 is hydrogen, halogen or lower alkyl,
• R2 is hydrogen, halogen or lower alkyl,
• R3 is halogen or lower alkyl, which lower alkyl is optionally substituted by halogen,
• R4 is a) lower alkyl, optionally substituted by halogen or lower alkoxy,
• b) lower alkoxy, optionally substituted by halogen, hydroxyl, cycloalkyl or heterocyclyl,
• c) —Si(lower alkyl)3,
• d) —O-cycloalkyl, optionally substituted by halogen, amido, nitro, acetyl, acetamidyl, lower alkyl, halogen-lower alkyl, lower alkoxy-lower alkyl, lower alkoxy, halogen-lower alkoxy, —NR11R12, or —S(O)2-lower alkyl,
• e) —O-aryl, optionally substituted by halogen, amido, nitro, acetyl, acetamidyl, lower alkyl, halogen-lower alkyl, lower alkoxy-lower alkyl, lower alkoxy, halogen-lower alkoxy, —NR11R12, or —S(O)2-lower alkyl,
• f) —O-heteroaryl, optionally substituted by halogen, amido, nitro, acetyl, acetamidyl, lower alkyl, halogen-lower alkyl, lower alkoxy-lower alkyl, lower alkoxy, halogen-lower alkoxy, —NR11R12, or —S(O)2-lower alkyl,
• g) —O-heterocyclyl, optionally substituted by halogen, amido, nitro, acetyl, acetamidyl, lower alkyl, halogen-lower alkyl, lower alkoxy-lower alkyl, lower alkoxy, halogen-lower alkoxy, —NR11R12, or —S(O)2-lower alkyl,
• wherein each S being part of a heterocyclyl is optionally substituted by oxo,
• h) heteroaryl, optionally substituted by halogen, amido, nitro, acetyl, acetamidyl, lower alkyl, halogen-lower alkyl, lower alkoxy-lower alkyl, lower alkoxy, halogen-lower alkoxy, —NR11R12, or —S(O)2-lower alkyl,
• i) aryl, substituted by halogen, amido, nitro, acetyl, acetamidyl, lower alkyl, halogen-lower alkyl, lower alkoxy-lower alkyl, lower alkoxy, halogen-lower alkoxy, —NR11R12, or —S(O)2-lower alkyl, or
• j) heterocyclyl, optionally substituted by halogen, amido, nitro, acetyl, acetamidyl, lower alkyl, halogen-lower alkyl, lower alkoxy-lower alkyl, lower alkoxy, halogen-lower alkoxy, —NR11R12, or —S(O)2-lower alkyl,
• and R4 is hydrogen when R10 is phenyl, wherein the phenyl is optionally substituted by halogen, lower alkyl, or —S(O)2-lower alkyl,
• and R4 is aryl when R6 is lower alkyl,
• R5 is halogen or lower alkyl,
• R6 is hydrogen or lower alkyl,
• R7 is hydrogen or lower alkyl,
• R8 is hydrogen or lower alkyl,
• R9 is hydrogen, halogen, lower alkyl or lower alkoxy,
• R10 is hydrogen, halogen, lower alkyl or lower alkoxy,
• R11 is hydrogen or lower alkyl,
• R12 is hydrogen or lower alkyl,
• X is a) N and Y is C—R10, or
• b) C—R9 and Y is N, and
• n is 0 or 1,
• with the proviso that R8 is lower alkyl, when
• a) R1 is hydrogen, R2 is hydrogen, R3 is chloro, R4 is hydrogen, R6 is methyl, R7 is hydrogen, R9 is hydrogen, n is 0, X is C—R9 and Y is N;
• or
• b) R1 is hydrogen, R2 is hydrogen, R3 is chloro, R4 is hydrogen, R6 is methyl, R7 is hydrogen, R10 is hydrogen, n is 0, X is N and Y is C—R10;
• or a pharmaceutically active salt thereof and a pharmaceutically acceptable carrier.